Halo Pharmaceutical to establish new Canadian subsidiary

Halo Pharmaceutical, a provider of contract manufacturing, formulation development and laboratory testing services, has announced that it is establishing a new Canadian subsidiary to be called Halo Pharmaceutical Marketing Canada, which will have its headquarters in Ontario.

Halo Pharmaceutical Marketing Canada’s main purpose will be the marketing, sale and distribution of branded pharmaceutical products currently available in other major markets but not marketed in Canada.

Halo said that it is seeking, evaluating and moving forward with opportunities for in-licensing and for the acquisition of branded products for both the US and Canadian markets from companies looking to rationalize their product portfolios. The Canadian subsidiary will be structured as a joint venture with CB&A, a Canadian entity also based in Ontario, Canada.

Halo has also named Clive Bennett as the president and CEO of this Canadian entity. Mr Bennett, a Canadian pharmaceutical executive, has over 38 years of experience in the global pharmaceutical industry. Prior to joining Halo Mr Bennett worked for Patheon for seven years. He held various top level positions at Patheon including the roles of chief scientific officer, president of Patheon USA and president of Mova Pharmaceutical, a subsidiary of Patheon.

Mohd Asif, CFO of Halo Pharmaceutical, said: We are excited about the opportunity to market a number of products in Canada as we continue to grow our North American business.